Condition
HPV-unrelated Head and Neck Squamous Cell Carcinoma
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
6 treatments under study, led by Paclitaxel
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 2 (1)
Phase 3 (1)
Trial Status
Not Yet Recruiting1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT04966481Phase 3RecruitingPrimary
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
NCT07776340Phase 2Not Yet RecruitingPrimary
Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC
Showing all 2 trials
Research Network
Common Treatments
- Paclitaxel1
- Palbociclib1
- Cisplatin1
- Tislelizumab1
- Cetuximab1
Active Sponsors
- Washington University School of Medicine1
- The Joseph Sanchez Foundation1
- Pfizer1
- Fudan University1
Top Investigators
Washington University School of Medicine